Company / Operating Margin
Immix Biopharma, Inc. Operating Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-113.4%
FY2025
5-year range
-113.4% / -41.1%
FY2023-FY2025
Trend
-40.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -41.1% to -113.4% over the past 2 years.
Based on SEC 10-K filings.
-113.4% in FY2025.
Declined from -41.1% to -113.4% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin decreased 40.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -113.4% | -40.5% |
| FY2024 | -80.7% | -96.4% |
| FY2023 | -41.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026